|
For immediate release
|
27 June
2024
|
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Grant of Options to
Directors
Alliance Pharma plc (AIM: APH), the
international healthcare group, announces that the Board has
issued options over 906,862 ordinary shares of 1 pence each in the
Company, on the recommendation of the Company's Remuneration
Committee, to Nick Sedgwick, pursuant to the Company's Long-Term
Incentive Plan 2019.
The awards have been granted at nil-cost and become
exercisable on 24 June 2027 subject always to continued employment
and the satisfaction of performance conditions based on EPS, TSR
and ROCE targets.
The notification below, made in
accordance with the requirements of the UK Market Abuse Regulation,
provides further detail.
Notification and public disclosure of transactions by person
discharging managerial responsibilities.
|
1
|
Details of the
person discharging managerial responsibilities/person closely
associated
|
|
a)
|
Name
|
Mr Nick Sedgwick
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Executive Officer - PDMR
|
|
b)
|
Initial notification /Amendment
|
Initial Notification
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Alliance Pharma plc
|
|
b)
|
Legal Entity Identifier
|
N/A
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary shares of 1.0 pence each
ISIN: GB0031030819
|
|
b)
|
Nature of the transaction
|
Grant of Options
|
|
c)
|
Currency
|
GBP
|
|
d)
|
Price(s) and volume(s)
|
Exercise Price
(p)
|
No. of share
options
|
|
Nil
|
906,862
|
|
|
|
|
|
|
e)
|
Aggregated information
- Aggregated volume
- Price
- Aggregated total
|
Grant of 906,862 options to acquire ordinary
shares of 1 pence each at nil-cost.
|
|
f)
|
Date of the transaction
|
24 June 2024
|
|
g)
|
Place of the transaction
|
Outside of trading venue
|
For
further information:
|
Alliance Pharma plc
|
+ 44 (0)1249
466966
|
|
Head of Investor Relations: Cora
McCallum
|
+ 44
(0)1249 705168
|
|
ir@allianceph.com
|
|
|
www.alliancepharma.co.uk
|
|
|
Buchanan
|
+ 44 (0)20 7466
5000
|
|
Mark Court / Sophie Wills
|
|
|
alliancepharma@buchanan.uk.com
|
|
|
|
|
|
Numis Securities Limited (Nominated Adviser and Joint
Broker)
|
+ 44 (0)20 7260
1000
|
|
Nominated Adviser: Freddie Barnfield
/ Duncan Monteith / Sher Shah
|
|
|
|
|
|
Investec Bank plc (Joint Broker)
|
+ 44 (0)20 7597
5970
|
|
Patrick Robb / Maria Gomez de
Olea
|
|
About Alliance
Alliance Pharma plc (AIM:
APH) is a growing consumer healthcare
company. Our
purpose is to empower people to make a positive difference to their
health and wellbeing by making our trusted and proven brands
available around the world.
We deliver organic growth through
investing in our priority brands and channels, in related
innovation, and through selective geographic expansion to increase
the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary
acquisitions.
Headquartered in the UK, the Group
employs around 285 people based in locations across Europe, North
America, and the Asia Pacific region. By outsourcing our
manufacturing and logistics we remain asset-light and focused on
maximising the value we can bring, both to our stakeholders and to
our brands. For more information on
Alliance, please visit our website: www.alliancepharmaceuticals.com